Objective: The objective of this study was to examine the expression of deubiquitylases USP29 in thymomas with myasthenia gravis (MG) and research associated immunological processes.
Methods: 69 MG patients with thymomas, 21 thymoma patients without MG, and 31 healthy controls were classified into three groups (categories): group with MG-associated thymoma (MG-T), group with non-MG-associated thymoma (NMG-T), and group with healthy controls (HC). In thymomas, the mRNA and protein levels of RORγt and USP29 were examined by real-time reverse transcription polymerase chain reaction (real-time RT-PCR) and western blotting. Th17 cell counts in MG patients with thymomas were investigated by flow cytometry.
Results: In MG-related thymomas, the mRNA and protein levels of deubiquitylases USP29 were substantially elevated. USP29 post-transcriptionally regulated RORγt. In MG patients with thymomas, the expression of USP29 was positively linked to the RORγt expression and Th17 cell frequency.
Conclusion: This work exhibited that the elevated USP29 enhanced RORγt expression, which in turn affected the Th17 cell growth in thymomatous MG. Our data suggest that USP29 might take part in the regulation of RORγt expression and Th17 cell generation and constitute an innovative regulatory function for USP29 in autoimmune disease.
Keywords: Deubiquitinase; RORγt; Th17 cells; USP29; myasthenia gravis; thymoma.
AJTR Copyright © 2022.